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Background: Polypharmacy is considered the most important etiologic factor of hyposalivation, which in
turn can initiate oral health problems.
Objectives: To describe the medication use of nursing home residents, to identify the medications related
to hyposalivation and to ﬁnd possible associations between the different classes of medication, the
number of medications, and the oral health status of the residents.
Design: A cross-sectional study.
Participants: The study population consisted of the residents of a nonrandom sample of 23 nursing
homes from 2 Belgian provinces, belonging to the oral health care network Gerodent. All residents of the
sample visited the Gerodent mobile dental clinic between October 2010 and April 2012.
Measurements: For each resident, oral health data, demographic data, and an overview of the total
medication intake were collected.
Results: The study sample consisted of 1226 nursing home residents with a mean age of 83.9 years
[standard deviation (SD) 8.5]. The mean number of medications per person was 9.0 (SD 3.6, range 0-23,
median 9.0). Of all prescribed medication, 49.6% had a potential hyposalivatory effect with a mean
number per person of 4.5 (SD 2.2, range 0-15, median 4.0). In the bivariate analyses, associations were
found between medication use and oral health of residents with natural teeth: the higher the number
of medications (with risk of dry mouth) and the overall risk of medication-related dry mouth, the
lower the number of natural teeth (P ¼ .022, P ¼ .005, and P ¼ .017, respectively). In contrast, the total
treatment need tended to decrease with rising medication intake, resulting in a clear increase of the
treatment index with rising medication intake (P ¼ .003, P < .001 and P ¼ .002). The logistic regression
model analysis conﬁrmed that the proportion of carious teeth diminished and the treatment index
increased in case of rising medication intake, especially when considering the number of medications
with a risk of dry mouth and the overall risk of medication-related dry mouth. A possible explanation
for this trend might be the ﬁnding that in the group with a high medication use, the teeth most
sensitive to caries and plaque retention could already have been extracted at the moment of screening
for the study, because of a lifelong history of caries pathology.
Conclusions: This study shows a high level of medication use, including the substantial intake of medi-
cation with a possible hyposalivatory effect. Moreover, clear associations were found between the
medication intake and the oral status of the residents.
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diseases, disability, frailty and considerable care dependency. Corre-
spondingly, the majority of them suffers from cognitive impairment
and requires assistance with activities of daily living (ADL). In addi-
tion, the complex care for these residents is further challenged by the
high prevalence of pain, depression, behavioral and psychological
symptoms, urinary incontinence, malnutrition, falls, and pressure ul-
cers.1 Consequently, the pharmacologic treatment of nursing home
residents often results in polypharmacy.2 Elseviers et al3 reported that
the mean number of medications per resident in Belgium was 8.4 in
the year 2010. Only 1% of the residents took no medication and
one-third were prescribed 10 or more medications. The most recur-
rent chronic medication types were hypnosedatives (61%), antide-
pressant agents (50%), and laxatives (50%). Similar results were found
in other countries.4e7
Polypharmacy is considered the most important etiologic factor of
hyposalivation. Other etiologic factors are age-related degenerative
changes in the salivary glands8e13 and several systemic disorders such
as diabetes, depression, Parkinson disease, Alzheimer disease, rheu-
matoid arthritis, and nutritional deﬁciencies.14e17 Not only the type
but also the number of medications has an impact, causing decreasing
salivary ﬂow rates as the number of medications increases.18,19
Previous studies investigatedmedication usewith a hyposalivatory
side effect in community-dwelling older people.18e21 However, the
only similar study in nursing home residents to date, which measured
salivary ﬂow, had a limited sample size22 and other studies in nursing
homes only reported on the prevalence of xerostomia (the feeling of a
dry mouth) in relation to medication use.23,24 So far, few studies have
discussed the prevalence of salivary gland hypofunction in nursing
home residents. A study of Glazar et al25 showed that 27% of the
residents suffered from hyposalivation. A second study of van der
Putten et al22 stated that 24% had an unstimulated whole saliva below
0.1 mL/min. A common and primary symptom of salivary gland
hypofunction or hyposalivation is xerostomia, the subjective feeling of
dry mouth. The prevalence of xerostomia among nursing home resi-
dents varies between 36% and 52%, depending on the study.22,24,26,27
Unfortunately, all studies on salivary ﬂow or xerostomia in nursing
homes exclude cognitively impaired residents, because they could not
follow instructions to measure salivary ﬂow or answer the xerostomia
questions, and therefore these studies cannot be considered repre-
sentative for the overall nursing home population.
A recent systematic review addressed the oral healtherelated
clinical implications of medication-induced salivary gland dysfunction
in the general population.28 The authors stated that more research on
this topic is needed, although several studies indicated a possible
relationship between xerogenic medication and caries activity. Two
recent studies of Tiisanoja21,29 have uncovered an association between
salivary ﬂow and dental caries in older persons taking medication
with sedative properties: the higher the sedative load, the higher the
caries activity and the lower the salivary ﬂow. Bardow et al19
demonstrated that low unstimulated ﬂow rates lead to higher levels
of both Lactobacilli and tooth demineralization, which risks rapid
caries progression. Dental restoration rate, reﬂection of caries inci-
dence history, and intake of medication have also been indicated to be
related: persons taking medication had higher restoration rates
compared to those not taking medication.30,31 Moreover, persons
taking antidepressant xerogenic medication had higher restoration
rates, compared to those taking nonxerogenic medication.31 In
contrast with caries, no clear relationship between salivary ﬂow and
periodontal infection or oral mucosal changes has been found.29,32
As previously stated by several authors,18,30 there is a clear need to
further exploremedication classes and their potential associationwith
salivary gland hypofunction and impairment of oral health. Moreover,
scarce attention has yet been devoted to oral consequences of a dry
mouth in nursing home residents.The aim of this study is ﬁrst to describe the medication use in a
sample of nursing home residents in order to identify the medications
related to hyposalivation and, second, to ﬁnd possible associations
between the different classes and numbers of medications and the
oral health status of the residents.
Materials and Methods
Study Design, Study Population, and Study Sample
The present study is a cross-sectional study approved by the
Ethical Committee of the Ghent University Hospital (B670201318461).
The study population consisted of nursing home residents from East
and West Flanders, 2 Belgian provinces, from which a sample of 23
nursing homes was obtained, which all belong to the oral health care
network Gerodent. More information on the oral health care network
is described in a previous article by Janssens et al.33
Data Collection
One of the tasks of the Gerodent oral health care network is
providing preventive and curative oral care for nursing home resi-
dents. The data for this study were extracted from the oral health
records of the nursing home residents attending the mobile dental
clinic for a ﬁrst consultation between October 2010 and April 2012.
The oral assessment was performed by one of the 3 dentists of the
Gerodent team (B.J., J.V., and L.D.V.), all of whom are experienced in
geriatric dentistry andworked as a team. The oral health data included
the number of natural teeth, dental caries, residual roots, ﬁlled teeth,
the D3MFt (sum of teeth with visually obvious dental decay in the
dentine of the tooth D3, missing teeth M, and ﬁlled teeth F), the
restorative index [F/(D3þF)], information about the presence of
denture-related pressure ulcers and removable dentures as well as an
oral treatment needs assessment comprising the need for ﬁllings and
extractions, the treatment index [(F þM)/(D3 þM þ F)], and the need
for repair, rebasing or renewal of a removable denture. The oral health
status was diagnosed in a fully equipped mobile dental unit with a
portable dental operating light (Aseptico) and a mobile x-ray device
(Rextar EXO1414). More information on how the data of the oral status
were gathered can be found in the previously mentioned study.33
Subsequently, age, gender, care dependency (KATZ scale34), and
increased reimbursement were extracted from the medical records of
the participating residents, which were kept by the caring staff and
physician of the nursing home. Increased reimbursement is a
governmental measure for persons whose income is below a certain
limit, and who are thus entitled to a higher reimbursement for health
care interventions. For the analysis, 3 levels of care dependency were
deﬁned as follows: low (KATZ O and A), medium (KATZ B), and high
(KATZ C and Cd).
Only the residents with an overview of the total medication intake
in their oral health recordswere considered for analysis. This overview
was obtained by a print of the nursing homes’ medication lists. For
each resident, the medication was classiﬁed by the Anatomical Ther-
apeutic Chemical (ATC) classiﬁcation system from the WHO Collabo-
rating Centre for Drug Statistics Methodology.35 This classiﬁcation
systemwas designed as a tool for presenting drug utilization statistics
and classiﬁes drugs into groups at 5 different levels: 14 anatomical
main groups (level 1), therapeutic/pharmacologic subgroups (level 2),
chemical/pharmacologic/therapeutic subgroups (levels 3 and 4), and
chemical substance (level 5). Complementary, homeopathic, and
herbal traditional medicinal products are generally not included in the
ATC classiﬁcation system and were not considered as medication in
this study, even if they occurred on the medication list of the resident.
For this analysis, the prescribed daily dose and the duration of use
were not considered.
Table 1
Number of Persons Taking 1 or More Drugs From the Different Groups of the ATC
Classiﬁcation System (Total n ¼ 1174)*
ATC Code n (%)
Alimentary tract and metabolism 1006 85.69
A02 Drugs for acid-related disorders 533 45.4
A03 Drugs for functional gastrointestinal disorders 173 14.74
A06 Drugs for constipation 620 52.81
A07 Antidiarrheals, intestinal anti-inﬂammatory/
anti-infective agents
87 7.41
A10 Drugs used in diabetes 212 18.06
A10a Insulins and analogues 212 18.06
A11 Vitamins 186 15.84
A12 Mineral supplements 219 18.65
Blood and blood-forming organs 704 59.97
B01 Antithrombotic agents 655 55.79
B01AA Vitamin K antagonists 127 10.82
B01AB Heparin group 45 3.83
B01AC Platelet aggregation inhibitors excl. heparin 508 43.27
B02 Antihemorrhagics 4 0.34
B03 Antianemic preparations 108 9.2
Cardiovascular system 954 81.26
C01 Cardiac therapy 310 26.41
C02 Antihypertensives 35 2.98
C03 Diuretics 510 43.44
C07 Beta blocking agents 438 37.31
C08 Calcium channel blockers 217 18.48
C09 Agents acting on the renin-angiotensin system 317 27
C10 Lipid modifying agents 295 25.13
Genitourinary system and sex hormones 130 11.07
G04 Urologicals 109 9.28
Systemic hormonal preparations, excl. sex hormones
and insulins
178 15.16
H02 Corticosteroids for systemic use 78 6.64
H03 Thyroid therapy 103 8.77
Anti-infectives for systemic use 137 11.67
J01 Antibacterials for systemic use 134 11.41
Musculoskeletal system 271 23.08
M01 Anti-inﬂammatory and antirheumatic products 79 6.73
M04 Antigout preparations 72 6.13
M05 Drugs for treatment of bone diseases 92 7.84
M05b Drugs affecting bone structure and
mineralization
92 7.84
M05ba Bisphosphonates 52 4.43
M05BB Bisphosphonates, combinations 20 1.7
M05BX Other drugs affecting bone structure
and mineralization
20 1.7
Nervous system 1080 91.99
N02 Analgesics 547 46.59
N03 Antiepileptics 138 11.75
N04 Anti-Parkinson drugs 156 13.29
N05 Psycholeptics 804 68.48
N05a Antipsychotics 393 33.48
N05b Anxiolytics 428 36.46
N05c Hypnotics and sedatives 331 28.19
N06 Psychoanaleptics 661 56.3
N06a Antidepressants 545 46.42
N06d Anti-dementia drugs 191 16.27
Respiratory system 299 25.47
R03 Drugs for obstructive airway diseases 150 12.78
R05 Cough and cold preparations 93 7.92
R06 Antihistamines for systemic use 96 8.18
Sensory organs 121 10.31
S01 Ophthalmologicals 119 10.14
*This table only mentions the medications with an intake prevalence higher than
6% or medications related to dental treatment.
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total number of medications, the total number of medications with a
risk of dry mouth and the total risk of dry mouth. To deﬁne the risk of
any hyposalivatory effect of each medication in the database, the
search engine of www.drymouth.info was used. This database is a
valuable resource that is updated on a yearly basis.36 Sources include
the reference guide to drugs and dry mouth of Sreebny et al,37 the US
Food and Drug Administration and medical and dental drug reference
guides. The search engine also provides information on the risk of the
medication to induce oral dryness as a score ranging from 1 to 3
(indicated by cactus symbols). For the purpose of this study, the total
risk of dry mouth was deﬁned by the sum of the individual risk scores
(1-3) of each medication on the residents’ medication list.
A study by Smidt et al18 measuring the salivary ﬂow rates of 688
medicated older persons served as a basis to select speciﬁc medication
(classes) for the assessment of the association between medication use
and impaired oral health. The speciﬁc medication (classes) considered
were antidiabetics (A10), sulfonamides (A10BB), antithrombotic agents
(B01), cardiac therapy (C01), thiazides (C03AA), verapamil (C08DA), anti-
hypertensives and antidiabetics and statins [(C03þ/-C07C08
C09A12) þ A10 þ C10A], acetylsalicylic acid and lipid-lowering drugs
(B01AC06 þ C10), antirheumatics (M01AX), opioids (N02AX), psycho-
leptics (N05), psychoanaleptics (N06), selective serotonin reuptake in-
hibitors (N06AB), psycholeptics and psychoanaleptics (N05 þ N06),
respiratory drugs (R03), glucocorticoids (R03BA), and respiratory drugs
and antihypertensives [R03þ (C03C07 C08C09A12)].
Statistical Analysis
Descriptive analyses of the residents’ medication use were per-
formed. To explore the impact of the explanatory variables such as age,
gender, care dependency, and increased reimbursement on the
number of medications (with risk of dry mouth) and the overall risk of
drymouth,1-way analyses of variancewere performed. To explore the
impact of the explanatory variables on the speciﬁc medication classes,
as described in the previous paragraph, chi-square tests were imple-
mented. Nonparametric Kruskal-Wallis tests were conducted to
examine the impact of medication use on the dependent variables
deﬁned as oral health status and the treatment needs of the dentate
residents, as the data did not meet the assumption of normality ac-
cording to the Shapiro-Wilk normality test. If applicable, the outcome
variables were corrected for the number of remaining natural teeth. In
this case, they have to be considered as a part in relation to the total
number of remaining natural teeth. Finally, a logistic regression model
analysis was performed with the nursing home as random effect. Age,
gender, care dependency, increased reimbursement, number of
medications, number of medications with risk of dry mouth, and total
risk of dry mouth were introduced as explanatory variables. The
outcome variables were corrected for the number of remaining nat-
ural teeth and dichotomized by the median value. Tests resulting in P
values <.05 were considered signiﬁcant. All analyses were carried out
using SPSS for windows version 22 (SPSS Inc, Chicago, IL).
Results
The study sample consisted of 1226 residents of 23 different
nursing homes with a mean age of 83.9 years (standard deviation 8.5),
of whom 858 (70.0%) were female. The medication list was available
for 1174 residents. The mean number of medications per person was
9.0 (standard deviation 3.6, range 0-23, median 9.0). Of all prescribed
medication, 49.6% had a potential hyposalivatory effect with a mean
number per person of 4.5 (standard deviation 2.2, range 0-15, median
4.0). Only 1.4% of the study sample took no medication with a po-
tential hyposalivatory effect; one person took no medication at all.
There was a signiﬁcant difference in mean number of medications perresident between the different nursing homes ranging from 7.71 to
10.94 (P < .001).
Medication Use
Table 1 gives an overview of the residents’ medication intake, with
n being the number of residents taking 1 or more medications from
the corresponding group of the ATC classiﬁcation system. Many
Table 2
Medication Intake by Sociodemographic Groups and Care Dependency in the Total Group (n ¼ 1174)
Variables n % Number of
Medications
Number of Medications
With Risk of Dry Mouth
Risk of Dry
Mouth
Mean (SD) Mean (SD) Mean (SD)
Gender 1174
Male 352 29.98 8.81 (3.57) 4.32 (2.07) 6.19 (3.50)
Female 822 70.02 9.07 (3.64) 4.55 (2.23) 6.50 (3.71)
P value* .265 .089 .185
Age 1174
<Mean age (83.9 years) 501 42.67 9.21 (3.64) 4.69 (2.26) 6.81 (3.84)
>Mean age (83.9 years) 673 57.33 8.83 (3.59) 4.32 (2.12) 6.10 (3.48)
P value* .076 .004 .001
Care dependency 1170
Low (Katz O and A) 205 17.52 9.44 (3.88) 4.97 (2.34) 6.98 (4.06)
Medium (Katz B) 319 27.26 9.28 (3.61) 4.68 (2.20) 6.66 (3.69)
High (Katz C and Cd) 646 55.21 8.70 (3.51) 4.23 (2.10) 6.10 (3.47)
P value* .009 <.001 .004
Increased reimbursement 1174
No 378 32.2 8.59 (3.44) 4.35 (2.10) 6.18 (3.46)
Yes 796 67.8 9.18 (3.68) 4.55 (2.23) 6.51 (3.74)
P value* .008 .146 .143
Natural teeth 1174
No 688 58.6 8.88 (3.57) 4.50 (2.25) 6.45 (3.80)
Yes 486 41.4 9.15 (3.67) 4.46 (2.10) 6.35 (3.45)
P value* .197 .748 .656
Note. Bold values are statistically signiﬁcant P < .05.
SD, standard deviation.
*One-way analysis of variance.
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cardiovascular diseases (C, n ¼ 954, 81.3%), diabetes mellitus type 2
(A10, n ¼ 212, 18.1%), dementia (N06d, n ¼ 191, 16.3%), Parkinson
disease (N04, n ¼ 156, 13.3%), and obstructive airway diseases (R03,
n ¼ 150, 12.8%).
Of the total study sample, 655 persons (55.79%) took antith-
rombotic agents (B01) and 92 persons (7.84%) were using medication
that affects bone structure and mineralization (M05b), which
impacted the dental extraction protocol because of the risk of bleeding
and medication-related osteonecrosis of the jaw, respectively. A high
use of psycholeptics (N05, n ¼ 804, 68.5%), psychoanaleptics (N06,
n¼ 661, 56.3%), and analgesics (N02, n¼ 547, 46.6%) was registered as
well as a considerable intake of medication for constipation (A06,
n ¼ 620, 52.8%) and stomach aciderelated disorders (A02, n ¼ 533,
45.4%).
Bivariate Analysis
By assessing the association between gender, age, care de-
pendency, increased reimbursement, and the presence of natural
teeth and the variables related to the medication intake, this study
revealed that gender and presence of natural teeth were not corre-
lated with medication intake (Table 2). In contrast, an association was
indeed found between age, care dependency, and increased reim-
bursement: residents older than the mean age took less medication
with a risk of dry mouth (P ¼ .004) and had a lower overall risk of dry
mouth (P < .001); residents with an increased reimbursement took
more medication than those without an increased reimbursement
(P ¼ .008); and a higher care dependency lead to a lower number of
medications (P ¼ .009), a lower number of medication with risk of dry
mouth (P < .001), and a lower overall risk of dry mouth (P ¼ .004).
Within the group of residents with natural teeth, there was a clear
association between the number of teeth and the medication intake:
the higher the number of medications (with risk of dry mouth) and the
overall risk of dry mouth, the lower the number of natural teeth
(P ¼ .022, P ¼ .005, and P ¼ .017, respectively; Table 3). In contrast, the
total treatment need tended to decrease in case of increasing medica-
tion intake, which resulted in a clear rise of the treatment index in caseof increasing medication intake (P ¼ .003, P < .001 and P ¼ .002). No
other oral health and treatment need indicators collected in this study
were associated with the variables expressing the medication intake.
Logistic Regression Model Analysis
The logistic regression model analysis, as shown in Table 4,
conﬁrmed that the proportion of carious teeth decreased and the
treatment index rose in case of increasedmedication intake, especially
when considering the number of medications with a risk of drymouth
(P < .001 to P ¼ .017) and the overall risk of dry mouth (P < .001 to
P ¼ .060).
Discussion
The ﬁrst aim of the present study was to describe the medication
use of the nursing home residents in our sample and to identify the
hyposalivation-related medication. The results conﬁrm the hypothe-
sized high medication use of nursing home residents in Belgium,
previously described in the Prescribing in Homes for the Elderly in
Belgium (PHEBE) study.3,38 Themean numbers of medications and the
characteristics of the study sample in both studies were comparable.
As in the PHEBE study, there were no clear associations between
gender and age on the one hand, and medication intake on the other.
In contrast, both studies found decreasingmedication intake in case of
increasing care dependency (including the degree of dementia) and
signiﬁcant differences in medication intake between nursing homes.
Based on the data collected in this study, we cannot assess whether
the decrease of intake for highly dependent and demented residents
was due to considered and justiﬁed therapeutic abstinence or
undertreatment of certain conditions. Concerning the discrepancy
between nursing homes, the PHEBE study observed differences
depending on the ﬁnancial structure, the supplier of the medication,
and the coordinating physician of the nursing home. The present
study did not collect this information, as it was considered to be
beyond its scope.
A study of Moore et al39 identiﬁed arterial hypertension, vascular
disease, dementia, arthritis, depression, and gastroesophageal reﬂux
Table 3
Distribution of Oral Health Indicators and Treatment Need Assessment by Medication Intake in the Dentate Group (n ¼ 712)*
Variables Number of Natural Teeth Total Treatment Need Natural Teethy Treatment Index (FþM) / (D3 þ M þF)
n % Mean (SD) n % Mean (SD) n % Mean (SD)
Number of medications 688 683 679
0-3 36 5.23 15.97 (9.16) 36 5.27 48.39 (38.24) 36 5.3 79.47 (22.02)
4-5 89 12.94 12.60 (8.53) 88 12.88 44.23 (40. 30) 88 12.96 84.85 (17.71)
6-7 137 19.91 12.96 (8.44) 136 19.91 40.47 (36.72) 134 19.73 85.16 (17.57)
8-9 135 19.62 12.74 (7.68) 133 19.47 37.27 (38.30) 132 19.44 87.87 (15.46)
10-13 221 32.12 10.93 (7.39) 220 32.21 39.41 (38.52) 219 32.25 89.35 (14.56)
14 70 10.17 12.16 (7.88) 70 10.25 29.02 (33.89) 70 10.31 89.97 (13.32)
P valuez .022 .090 .003
Number of medications
with risk of dry mouth
688 683 679
0-1 51 7.41 16.35 (8.58) 51 7.47 43.95 (34.78) 50 7.36 77.83 (22.03)
2-4 307 44.62 12.24 (7.98) 303 44.36 41.39 (38.79) 300 44.18 86.96 (15.59)
5-7 267 38.81 11.74 (7.88) 266 38.95 37.76 (37.90) 266 39.18 88.72 (15.46)
8 63 9.16 11.60 (7.37) 63 9.22 31.29 (36.57) 63 9.28 89.25 (15.44)
P valuez .005 .042 <.001
Risk of dry mouth 688 683 679
0-1 43 6.25 16.21 (8.94) 43 6.3 41.01 (33.46) 42 6.19 78.27 (22.56)
2-4 186 27.03 12.65 (8.48) 182 26.65 41.35 (38.75) 181 26.66 87.05 (15.89)
5-7 231 33.58 11.90 (7.51) 231 33.82 38.36 (37.94) 229 33.73 87.60 (15.57)
8-10 134 19.48 12.22 (7.78) 133 19.47 40.19 (39.04) 113 16.64 87.35 (16.38)
11 94 13.66 10.85 (7.77) 94 13.76 35.13 (37.61) 94 13.84 90.24 (14.16)
P valuez .017 .509 .002
Note. Bold values are statistically signiﬁcant P < .05.
SD, standard deviation.
*Only the outcome variables with signiﬁcant results (P < .05) are represented.
yThe outcome of this variable needs to be interpreted as part in relation to the total number of remaining natural teeth.
zKruskal-Wallis test.
B. Janssens et al. / JAMDA xxx (2017) 1.e1e1.e8 1.e5disease as the most prevalent comorbid conditions in a nursing home
setting. The medications to treat these conditions were highly prev-
alent in the present study. Polypharmacy is associatedwith potentially
inappropriate prescribing, which could lead to adverse drug effects
and unfavorable health outcomes.40,41 A recent systematic review,
only including studies conducted after 2005, reported that 49.8% of
the nursing home residents are exposed to potentially inappropriate
medication use.41 Considering the high number of medications in the
present study sample, similar results can be assumed. To reduce the
inappropriate prescribing, the attitude and nature of care settings and
the availability and feasibility of nondrug alternatives need to be
investigated.42
Both the medication use in general and the medication use with a
possible effect on dry mouth was exorbitant. These results are similar
to another smaller study22 and conﬁrm the suitability of the web tool
on www.drymouth.org to identify medication with a possible hypo-
salivatory effect.
The second aim of the present study was to ﬁnd possible associa-
tions between the different classes of medication, the number of
medications, and several variables of the residents’ oral health status.
As a consequence of the high medication use, only one person took no
medication, and therefore it was not possible to distinguish an
appropriate nonmedicated control group within the study sample.
When considering a subgroup of residents taking a speciﬁc type of
medication, the medication use was never limited to this speciﬁc type.
Moreover, it was only possible to compare them with residents not
taking the speciﬁc medication instead of comparing them to a non-
medicated control group. This hampered demonstrating the associa-
tion between a speciﬁc medication class and the clinical outcome
variables. Nevertheless, the number of medications with a risk of dry
mouth and the total risk of medication-related drymouthwere clearly
associated with the proportion of carious teeth and the treatment
index. The proportion of carious teeth was lower and the treatment
index was higher in case of increased medication intake, increased
medication intakewith a risk of drymouth, and a higher overall risk of
dry mouth. In the group with high medication use, the teeth most
sensitive to caries and plaque retention could already have beenextracted at the moment of screening for the study because of a life-
long history of caries pathology. This could explain the lower number
of teeth in this group. As a consequence, the remaining teeth may be
favorably positioned in the mouth to allow good cleaning. These re-
sults indicate the importance of taking preventive measures at the
start of medication intake for chronic conditions, which can lead to
tooth loss. Further research is needed to conﬁrm these results and to
ﬁnd other possible explanations for the observed results.
Strengths and Limitations
The strength of this study is its contribution to the actual knowl-
edge about the medication prescribed to nursing home residents. To
the authors’ knowledge, it was the ﬁrst study to distinguish the
medication with a possible hyposalivatory effect in a large sample of
this speciﬁc study population. Furthermore, the database and search
tool on the website drymouth.info clearly create opportunities for
further research. This article also manifestly identiﬁes barriers when
performing medication-related research in the nursing home
population.
Nevertheless, some limitations characteristic of this study setting
should be reported. A cross-sectional record of the medication use
alone will probably never result in a clear prediction of the conse-
quences of a low salivary ﬂow rate. A retro- or prospective longitu-
dinal observational design would be more appropriate. Moreover,
other possible reasons for salivary gland hypofunctionerelated un-
derlying diseases and/or nonpharmacologic treatments were not
considered. Because of the inclusion of many residents with cognitive
impairment, it was not possible to measure salivary ﬂow rate or the
prevalence of xerostomia. Finally, the deﬁned daily dose (DDD) or
prescribed daily dose (PDD) of the medications were not collected,
which may also be considered a limitation as it hampers the possi-
bility to draw conclusions regarding the dose-effect of the medica-
tions. The oral health indicators considered in this study are often
multifactorial and not exclusively associated with the use of medica-
tion or other parameters included in the mixed model analyses. The
living circumstances and diet are comparable for the residents within
Table 4
Mixed-Effect Logistic Regression Model Analysis* for the Proportion of Decayed
Teeth and the Treatment Index in the Dentate Group (n ¼ 712)
Variables (reference) Est b OR 95% CI OR P Value
Lower Upper
Proportion decayed teeth
Gender (male)
Female 0.46 0.63 0.45 0.89 .009
Age 0.03 1.03 1.01 1.05 .001
Number of medications (0-3)
4-5 0.65 0.52 0.23 1.20 .124
6-7 0.41 0.66 0.30 1.46 .308
8-9 0.88 0.41 0.19 0.91 .028
10-13 0.71 0.49 0.23 1.04 .065
14 0.71 0.49 0.21 1.16 .104
Number of medications with
risk of dry mouth (0-1)
2-4 0.78 0.46 0.24 0.87 .017
5-7 0.78 0.46 0.24 0.88 .018
8 0.98 0.38 0.17 0.83 .015
Risk of dry mouth (0-1)
2-4 1.01 0.36 0.18 0.75 .006
5-7 0.79 0.45 0.22 0.92 .029
8-10 0.71 0.49 0.23 1.03 .060
11 0.84 0.43 0.20 0.93 .033
Treatment index (FþM) / (D3 þ M þF)
Gender (male)
Female 0.65 1.92 1.36 2.72 <.001
Care dependency (low)
Medium 0.21 0.81 0.50 1.34 .412
High 0.49 0.61 0.39 0.94 .028
Number of medications (0-3)
4-5 0.56 1.75 0.76 4.01 .185
6-7 0.22 1.25 0.57 2.77 .582
8-9 0.43 1.54 0.70 3.42 .284
10-13 0.90 2.46 1.15 5.26 .020
14 0.76 2.14 0.90 5.05 .085
Number of medications with
risk of dry mouth (0-1)
2-4 1.25 3.49 1.67 7.32 .001
5-7 1.57 4.81 2.27 10.07 <.001
8 1.58 4.85 2.03 11.70 <.001
Risk of dry mouth (0-1)
2-4 1.07 2.92 1.34 6.42 .007
5-7 1.14 3.13 1.45 6.75 .004
8-10 1.12 3.06 1.36 6.82 .006
11 1.53 4.62 1.99 10.70 <.001
CI, conﬁdence interval; OR, odds ratio.
*The nursing home was introduced as a random effect and age, gender, care
dependency, preferential tariff, and 1 medication variable per analysis as explana-
tory variables. Only the explanatory variables presenting signiﬁcant results were
included in this table.
B. Janssens et al. / JAMDA xxx (2017) 1.e1e1.e81.e6the same nursing home, but important differences in the oral ﬂora and
dental plaque might not have been considered.
Future research should clarify if part of themedication intake could
be the result of general health problems due to bad oral health. To
date, many associations were shown between oral and general health
of the adult population up to 65 years old but no causal relationships
could be proven, and there is a lack of research in this area related to
frail older persons.
Conclusion
This study clearly shows the excessive level of medication use
including the high intake of medicationwith a possible hyposalivatory
effect and medications inﬂuencing dental treatment protocols. The
number of teeth and the proportion of decayed teeth were lower and
the treatment index was higher in case of increased medication
intake, increased medication intake with a risk of dry mouth, and a
higher overall risk of dry mouth.Acknowledgments
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Table A1
Number of Persons Taking 1 or More Drugs From the Different Groups of the ATC
Classiﬁcation System (Total n ¼ 1174)
ATC Code n (%)
Alimentary tract and metabolism 1006 85.69
A01 Stomatological preparations 10 0.85
A02 Drugs for acid related disorders 533 45.4
A03 Drugs for functional gastrointestinal disorders 173 14.74
A04 Antiemetics and antinauseants 0 0
A05 Bile and liver therapy 5 0.43
A06 Drugs for constipation 620 52.81
A07 Antidiarrheals, intestinal anti-inﬂammatory/
anti-infective agents
87 7.41
A08 Antiobesity preparations, excl. diet products 0 0
A09 Digestives, incl. enzymes 2 0.17
A10 Drugs used in diabetes 212 18.06
A10a Insulins and analogues 212 18.06
A10b Blood glucose lowering drugs, excl. Insulins 0 0
A10x Other drugs used in diabetes 0 0
A11 Vitamins 186 15.84
A12 Mineral supplements 219 18.65
A13 Tonics 0 0
A14 Anabolic agents for systemic use 4 0.34
A15 Appetite stimulants 0 0
A16 Other alimentary tract and metabolism products 1 0.09
Blood and blood-forming organs 704 59.97
B01 Antithrombotic agents 655 55.79
B01AA Vitamin K antagonists 127 10.82
B01AB Heparin group 45 3.83
B01AC Platelet aggregation inhibitors excl. heparin 508 43.27
B01AD Enzymes 0 0
B01AE Direct thrombin inhibitors 0 0
B01AF Direct factor Xa inhibitors 1 0.09
B01AX Other antithrombotic agents 0 0
B02 Antihemorrhagics 4 0.34
B03 Antianemic preparations 108 9.2
B05 Blood substitutes and perfusion solutions 7 0.6
B06 Other hematologic agents 0 0
Cardiovascular system 954 81.26
C01 Cardiac therapy 310 26.41
C02 Antihypertensives 35 2.98
C03 Diuretics 510 43.44
C04 Peripheral vasodilators 25 2.13
C05 Vasoprotectives 20 1.7
C07 Beta blocking agents 438 37.31
C08 Calcium channel blockers 217 18.48
C09 Agents acting on the renin-angiotensin system 317 27
C10 Lipid-modifying agents 295 25.13
Dermatologicals 47 4
D01 Antifungals for dermatological use 11 0.94
D02 Emollients and protectives 4 0.34
D03 Preparations for treatment of wounds and ulcers 0 0
D04 Antipruritics, incl. antihistamines, anesthetics, etc. 0 0
D05 Antipsoriatics 6 0.51
D06 Antibiotics and chemotherapeutics for
dermatologic use
3 0.26
D07 Corticosteroids, dermatologic preparations 21 1.79
D08 Antiseptics and disinfectants 3 0.26
D09 Medicated dressings 0 0
D10 Anti-acne preparations 0 0
D11 Other dermatologic preparations 0 0
Genitourinary system and sex hormones 130 11.07
G01 Gynecologic anti-infectives and antiseptics 5 0.43
G02 Other gynecologicals 0 0
G03 Sex hormones and modulators of the genital
system
19 1.62
G04 Urologicals 109 9.28
Systemic hormonal preparations, excl. sex hormones
and insulins
178 15.16
H01 Pituitary and hypothalamic hormones and
analogues
2 0.17
H02 Corticosteroids for systemic use 78 6.64
H03 Thyroid therapy 103 8.77
H04 Pancreatic hormones 0 0
(continued)
Table A1 (continued )
ATC Code n (%)
H05 Calcium homeostasis 3 0.26
Anti-infectives for systemic use 137 11.67
J01 Antibacterials for systemic use 134 11.41
J02 Antimycotics for systemic use 4 0.34
J04 Antimycobacterials 0 0
J05 Antivirals for systemic use 1 0.09
J06 Immune sera and immunoglobulins 0 0
J07 Vaccines 0 0
Antineoplastic and immunomodulating
agents
33 2.81
L01 Antineoplastic agents 11 0.94
L02 Endocrine therapy 19 1.62
L03 Immunostimulants 1 0.09
L04 Immunosuppressants 2 0.17
Musculoskeletal system 271 23.08
M01 Anti-inﬂammatory and antirheumatic
products
79 6.73
M02 Topical products for joint and muscular pain 8 0.68
M03 Muscle relaxants 41 3.49
M04 Antigout preparations 72 6.13
M05 Drugs for treatment of bone diseases 92 7.84
M05b Drugs affecting bone structure and
mineralization
92 7.84
M05ba Bisphosphonates 52 4.43
M05BB Bisphosphonates, combinations 20 1.7
M05BC Bone morphogenetic proteins 0 0
M05BX Other drugs affecting bone structure
and mineralization
20 1.7
M09 Other drugs for disorders of the
musculoskeletal system
1 0.09
Nervous system 1080 91.99
N01 Anesthetics 1 0.09
N02 Analgesics 547 46.59
N03 Antiepileptics 138 11.75
N04 Anti-Parkinson drugs 156 13.29
N05 Psycholeptics 804 68.48
N05a Antipsychotics 393 33.48
N05b Anxiolytics 428 36.46
N05c Hypnotics and sedatives 331 28.19
N06 Psychoanaleptics 661 56.3
N06a Antidepressants 545 46.42
N06b Psychostimulants, agents used for
ADHD and nootropics
20 1.7
N06c Psycholeptics and psychoanaleptics
in combination
28 2.39
N06d Anti-dementia drugs 191 16.27
N07 Other nervous system drugs 36 3.07
Antiparasitic products, insecticides, and repellents 7 0.6
P01 Antiprotozoals 7 0.6
P02 Anthelmintics 0 0
P03 Ectoparasiticides, incl. Scabicides,
insecticides, and repellents
0 0
Respiratory system 299 25.47
R01 Nasal preparations 22 1.87
R02 Throat preparations 3 0.26
R03 Drugs for obstructive airway diseases 150 12.78
R05 Cough and cold preparations 93 7.92
R06 Antihistamines for systemic use 96 8.18
R07 Other respiratory system products 0 0
Sensory organs 121 10.31
S01 Ophthalmologicals 119 10.14
S02 Otologicals 2 0.17
S03 Ophthalmologic and otologic preparations 1 0.09
Various 2 0.17
V01 Allergens 0 0
V03 All other therapeutic products 2 0.17
V04 Diagnostic agents 0 0
V06 General nutrients 0 0
V07 All other nontherapeutic products 0 0
V08 Contrast media 0 0
V09 Diagnostic radiopharmaceuticals 1 0.09
V10 Therapeutic radiopharmaceuticals 0 0
V20 Surgical dressings 0 0
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